Profile
Colin Scott was Vice President of Clinical Research and Development for NovaBay Pharmaceuticals, Inc. from January 2006 to December 31, 2008.
From October 2004 to December 2005, he was Vice President-Drug Development for GlycoMimetics.
From June 2004 to September 2004, Dr. Scott was a Consultant to several biopharmaceutical companies.
From September 2002 to May 2004, he served as the Vice President-Clinical and Regulatory at Arriva Pharmaceuticals, Inc. From March 2001 to May 2002, Dr. Scott served as Vice President-Clinical of Emisphere Technologies, Inc. He received a Medical degree in Pulmonology and Infectious Diseases from Glasgow University in Scotland.
Former positions of Colin Scott
| Companies | Position | End |
|---|---|---|
| NOVABAY PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2008-12-30 |
| GLYCOMIMETICS, INC. | Corporate Officer/Principal | 2005-11-30 |
Arriva Pharmaceuticals, Inc.
 Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California. | Chief Tech/Sci/R&D Officer | 2004-04-30 |
| EMISPHERE TECHNOLOGIES, INC. | Chief Tech/Sci/R&D Officer | 2002-04-30 |
Training of Colin Scott
| University of Glasgow | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| NOVABAY PHARMACEUTICALS, INC. | Health Technology |
| GLYCOMIMETICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Arriva Pharmaceuticals, Inc.
Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California. | Health Technology |
Emisphere Technologies, Inc.
 Emisphere Technologies, Inc. Pharmaceuticals: MajorHealth Technology Emisphere Technologies, Inc. is a commercial stage specialty pharmaceutical company, which engages in the development of new formulations of existing products and chemical entities, using Eligen Technology. Its product pipelines include eligen B12, eligen12.com, eligen B12 information, and purchase eligen B12. The company was founded in 1986 and is headquartered in Roseland, NJ. | Health Technology |
- Stock Market
- Insiders
- Colin Scott
